Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 98, Issue 5, Pages 489-491Publisher
WILEY-BLACKWELL
DOI: 10.1002/cpt.198
Keywords
-
Categories
Ask authors/readers for more resources
An early access pathway of conditional approval for potentially beneficial medicines is available within the European regulatory framework. However, marketing authorization does not necessarily result in recommendations for public funding by health technology assessment (HTA) agencies. As conditional approval goes along with less than complete data on benefits and risks of a treatment option for a high medical need, this raises the question how HTA decision-making is affected by these uncertainties.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available